Claims for Patent: 9,072,710

Summary for Patent: 9,072,710

Title:	Injectable ibuprofen formulation
Abstract:	The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.
Inventor(s):	Pavliv; Leo (Cary, NC), Vila; Andrew (Nashville, TN)
Assignee:	Cumberland Pharmaceuticals Inc. (Nashville, TN)
Application Number:	13/422,761
Patent Claims:	1. A pharmaceutical composition comprising an aqueous solution of ibuprofen, water for injection, and an ibuprofen solubilizing agent consisting of tribasic sodium phosphate, the aqueous solution being at a pH from 6.8 to 7.8, the molar ratio of tribasic sodium phosphate to ibuprofen being greater than 0.65:1to about 0.9:1, such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 4 mg/mL without undergoing a phase transition, and the pharmaceutical composition is clear, colorless and suitable for intravenous administration. 2. The pharmaceutical composition of claim 1, wherein the ibuprofen solubilizing agent is in a molar ratio to ibuprofen of about 0.9:1. 3. The pharmaceutical composition of claim 1, which shows no detectable chemical degradation after incubation for one month at 40.degree. C. 4. The pharmaceutical composition of claim 1, which is sterile filtered or terminally sterilized. 5. The pharmaceutical composition of claim 1, which can be stored at ambient conditions in prefilled polyolefin bags and remains clear and colorless for at least about 12 weeks. 6. The pharmaceutical composition of claim 1, which can be stored in a bag made from a pharmaceutically acceptable polymer for at least about 12 weeks at 4.degree. C. 7. The pharmaceutical composition of claim 1, which can be stored in a bag made from a pharmaceutically acceptable polymer for at least about 12 weeks at 25.degree. C. 8. The pharmaceutical composition of claim 1, which remains clear and colorless when stored in a bag made from a pharmaceutically acceptable polymer and exposed to a freeze-thaw cycle. 9. The pharmaceutical composition of claim 1, wherein the molar ratio of the ibuprofen solubilizing agent to the ibuprofen is from about 0.7 to about 0.9:1. 10. The pharmaceutical composition of claim 1, wherein the molar ratio of the tribasic sodium phosphate to ibuprofen is about 0.8:1. 11. The pharmaceutical composition of claim 1, wherein the aqueous solution of ibuprofen has been terminally sterilized. 12. The pharmaceutical composition of claim 1, wherein the pH of the aqueous solution of ibuprofen is from 7.07 to 7.60. 13. The pharmaceutical composition of claim 1, wherein the pH of the aqueous solution of ibuprofen is about 7.6. 14. The pharmaceutical composition of claim 1, wherein the aqueous solution comprises ibuprofen in a concentration from about 4 mg/mL to about 100mg/mL. 15. The pharmaceutical composition of claim 1, wherein the aqueous solution comprises ibuprofen in a concentration of from about 4 mg/mL to about 10 mg/mL. 16. The pharmaceutical composition of claim 1, wherein the aqueous solution is contained in a bag for intravenous administration, the bag containing 80 mL of the aqueous solution at an ibuprofen concentration from about 4 mg/mL to about 10 mg/mL. 17. The pharmaceutical composition of claim 1, wherein the aqueous solution is contained in a bag for intravenous administration, the bag containing 40 mL of the aqueous solution at an ibuprofen concentration from about 4 mg/mL to about 10 mg/mL. 18. The pharmaceutical composition of claim 1, wherein the aqueous solution is contained in a bag for intravenous administration, the bag containing ibuprofen at a concentration of from about 4 mg/mL to about 8 mg/mL and a volume selected from 100 mL or 50 mL. 19. A pharmaceutical composition contained in a pre-filled bag for intravenous use, comprising an effective dose of ibuprofen, water for injection, and an ibuprofen solubilizing agent consisting of tribasic sodium phosphate in a molar ratio of tribasic sodium phosphate to ibuprofen greater than 0.65:1 to about 0.9:1, the aqueous solution being at a pH from about 6.8 to about 7.8, the concentration of ibuprofen in the aqueous solution being from about 4 mg/mL to about 15 mg/mL, and the aqueous solution being clear and colorless, and suitable for intravenous administration. 20. The pharmaceutical composition of claim 19, wherein the pH of the aqueous solution of ibuprofen is from 7.07 to 7.60. 21. The pharmaceutical composition of claim 19, wherein the aqueous solution being contained in a bag made from a material selected from polypropylene, polyolefin and polyvinylchloride. 22. The pharmaceutical composition of claim 19, wherein the aqueous solution of ibuprofen contained in the bag is physically and chemically stable. 23. The pharmaceutical composition of claim 19, which comprises a dose of ibuprofen selected from 400 mg and 800 mg. 24. A method of preparing an aqueous solution of ibuprofen suitable for intravenous injection, comprising adding an ibuprofen solubilizing agent consisting of tribasic sodium phosphate to water for injection, mixing until the ibuprofen solubilizing agent is dissolved to form an aqueous solution of the ibuprofen solubilizing agent, adding ibuprofen to the solution such that the molar ratio of tribasic sodium phosphate to ibuprofen is greater than 0.65:1 to about 0.9:1 and the aqueous solution is at a pH from about 6.8 to about 7.8, and mixing until the ibuprofen is dissolved to form the aqueous solution of ibuprofen solubilizing agent and ibuprofen, such that the ibuprofen solubilizing agent maintains the ibuprofen soluble in the aqueous solution at concentrations from 100 mg/mL to 4 mg/mL without undergoing a phase transition and precipitating, and the aqueous solution is clear, colorless and suitable for intravenous administration. 25. The method of claim 24, further comprising adding sufficient water to the aqueous solution to result in a desired concentration of ibuprofen. 26. The method of claim 24, wherein the concentration of the ibuprofen in the aqueous solution is from about 4 mg/mL to about 100 mg/mL. 27. The method of claim 24, further comprising containing the aqueous solution in a bag for intravenous administration at an ibuprofen concentration from about 4 mg/mL to about 15 mg/mL and a dose from about 400 mg to about 800 mg. 28. The method of claim 24, wherein the pH of the aqueous solution is adjusted to a pH from 7.07 to 7.60. 29. A method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution comprising ibuprofen, water for injection, and an ibuprofen solubilizing agent consisting of tribasic sodium phosphate, the ibuprofen solubilizing agent being in an effective amount such that the molar ratio of tribasic sodium phosphate to ibuprofen is greater than 0.65:1 to about 0.9:1, the aqueous solution is at a pH from about 6.8 to about 7.8, and the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 4 mg/mL without undergoing a phase transition and precipitating, and the pharmaceutical composition is clear, colorless and suitable for intravenous administration. 30. The method of claim 29, wherein the effective amount of the aqueous solution comprises from about 5 mg to about 1000 mg of ibuprofen. 31. The method of claim 30, wherein the administration occurs via intravenous injection or via intramuscular injection. 32. The method of claim 29, wherein the administration occurs via intravenous injection or via intramuscular injection at a dose from about 400 mg to about 800 mg ibuprofen. 33. The method of claim 24, wherein the pH of the aqueous solution of ibuprofen is from 7.07 to 7.60. 34. The method of claim 29, wherein the pH of the aqueous solution of ibuprofen is from 7.07 to 7.60. 35. The pharmaceutical composition of claim 1, wherein the phase transition is selected from the aqueous solution turning hazy, a precipitate forming, and a mixture of the foregoing. 36. The pharmaceutical composition of claim 1, wherein the formulation further comprises sodium chloride. 37. The pharmaceutical composition of claim 19, wherein the ibuprofen solubilizing agent is in a molar ratio to ibuprofen of about 0.9:1.